Post-Infectious IBS: IBS After Food Poisoning, Recovery, Treatment and SIBO

In short: about 1 in 10 people develop irritable bowel syndrome (IBS) after a bout of gastroenteritis (an infection of the gut, often called food poisoning or a stomach bug), and their risk is about four times that of people who have not had one². The risk is highest after parasites such as Giardia, lower after bacteria and lowest after viruses. Many people improve over the years, but in long-term outbreak studies a large share still had IBS 8 to 10 years later⁸¹⁰. There is no treatment proven specifically for post-infectious IBSPost-infectious IBS Irritable bowel syndrome that starts after a bout of gastroenteritis (food poisoning or a stomach bug). It affects about 1 in 10 people after such an infection.; it is treated like other IBS of the same type¹. In animal studies the same infections also lead to SIBO, which is one reason the condition sits between the two.

This guide covers what post-infectious IBS is, how it is diagnosed, who gets it, how long it lasts, how it may link to SIBO and what the treatment trials show. For how SIBO and IBS overlap in general, see our SIBO vs. IBS guide.

What is post-infectious IBS?

IBS is a disorder of gut-brain interaction: recurring abdominal pain linked to changes in bowel habits, without a visible cause on standard tests. Post-infectious IBS is IBS that starts straight after an episode of gastroenteritis in someone who did not have IBS before¹.

In 2019, a working team of the Rome Foundation (the group that writes the international criteria for IBS) proposed diagnostic criteria based on the Rome IV criteria for IBS¹:

1. Recurrent abdominal pain on average at least 1 day a week in the last 3 months, with symptoms starting at least 6 months before diagnosis, linked to at least two of: bowel movements, a change in how often you go, or a change in how stools look.
2. Symptoms began immediately after the acute infection had cleared.
3. The infection was confirmed by a stool test, or, without one, there were at least two of fever, vomiting and diarrhea.
4. No IBS before the infection.

Most people with post-infectious IBS have diarrhea or a mix of diarrhea and constipation. In the 2017 meta-analysis described below, mixed IBS was the most common type (46%), followed by IBS with diarrhea (40%); IBS with constipation was the least common².

How common is it?

The best summary is a 2017 analysis of 45 studies that followed more than 21,000 people after infectious gastroenteritis²:

• 10.1% had IBS 12 months after the infection, and 14.5% at later time points.
• In the first year, the risk of IBS was 4.2 times that of people without a recent infection. More than a year later, it was 2.3 times higher.
• The studies varied a great deal, so these are averages across very different outbreaks and settings.

An earlier 2007 analysis of 18 studies found about 6 times the odds of IBS after a gut infection, with the excess risk smaller but still present 2 to 3 years later³.

How strictly IBS is defined matters. In a 2023 survey of 350 people in Minnesota 6 to 9 months after a confirmed Campylobacter infection, 17% met the stricter Rome IV criteria, while 30% would have met the older Rome III criteria⁷.

Which infections cause it?

A 2019 analysis of 34 studies found similar risks for the main food-poisoning bacteria, with 5.8 times the odds of IBS after bacterial gastroenteritis overall, and too few studies to judge viruses and parasites separately⁴.

Who is most at risk?

In the 2017 analysis, the risk of IBS after gastroenteritis was higher in²:

• Women: 2.2 times the odds.
• People who took antibiotics during the infection: 1.7 times the odds. This may partly reflect more severe infections being treated with antibiotics.
• People with anxiety (2 times) or depression (1.5 times), and people with a strong tendency to notice and worry about body symptoms.
• People with a more severe infection: diarrhea lasting more than a week (2.6 times the odds), abdominal pain during the illness or bloody stools. Fever and weight loss were not linked to IBS across studies.

In a long-term study of a 2000 outbreak in Walkerton, Canada, where the town’s water was contaminated with E. coli and Campylobacter, the risk factors for still having IBS 8 years later were female sex, younger age, anxiety or depression before the outbreak, and fever or weight loss during the illness⁸.

How long does post-infectious IBS last?

Many people improve, but it can last for years. The best data come from outbreaks where large groups were followed over time:

• Walkerton (bacteria): among 742 adults who had gastroenteritis in the outbreak, 28.3% had IBS after 2 to 3 years and 15.4% after 8 years. That was still about 3 times the rate in people who had not been ill⁸.
• Bergen, Norway (Giardia): after a 2004 waterborne outbreak, 39.4% of people with confirmed infection had IBS 6 years later, a little fewer than at 3 years⁹. At 10 years, 43% had IBS, compared with 14% of people from the same city who had not been infected; the rate had not fallen further after year 6¹⁰.
• Viruses: across studies, IBS after viral gastroenteritis was common in the first year but much less so afterwards².

The Rome working team advises reassuring people, especially after a viral infection, that symptoms are likely to improve or resolve over time in many cases¹.

What happens in the gut?

The mechanisms are not fully understood, and several probably act together¹:

• Low-grade inflammation. In a 2000 study that took repeated rectal biopsies from 21 people after Campylobacter infection, hormone-producing cells and immune cells (T lymphocytes) in the gut lining were increased, and the gut lining was more permeable (“leaky”). These changes could persist for more than a year and were also found in people with IBS after the infection¹¹.
• Changes in gut bacteria. In a 2014 study of 57 people, the stool bacteria of people with post-infectious IBS differed from those of healthy people and resembled those of people with diarrhea-predominant IBS¹².
• An antibody reaction against gut nerves. Many food-poisoning bacteria make a toxin called cytolethal distending toxin BCytolethal distending toxin B (CdtB) A toxin released by food-poisoning bacteria such as Campylobacter jejuni, E. coli and Salmonella. Antibodies against it can cross-react with vinculin and damage the gut nerves that run the migrating motor complex. (CdtB). Antibodies are proteins the immune system makes to recognise germs. In rats, antibodies made against CdtB also attach to vinculinVinculin A protein found in gut nerve cells. Anti-vinculin antibodies, which can form after food poisoning, are a marker of post-infectious IBS., a protein in gut nerve cells and in the pacemaker cells that coordinate gut movement¹⁵. Rats infected with Campylobacter lacking the toxin had fewer bowel changes than rats infected with the normal strain¹⁴.
• Weaker gut movement. Motility is the coordinated muscle activity that moves contents along the gut. Between meals, a wave called the migrating motor complexMigrating motor complex (MMC) A wave of muscle contractions that sweeps the stomach and small intestine between meals, roughly every 90 to 120 minutes, pushing leftover food and bacteria into the colon. Eating interrupts it. sweeps bacteria out of the small intestine, and its absence is associated with SIBO¹⁶.

How post-infectious IBS links to SIBO

The link is best shown in animals:

• In a 2008 rat study, Campylobacter infection led to bacterial overgrowth in the small intestine and changes in stool form 3 months after the infection had cleared¹³.
• In a 2010 follow-up, 27% of infected rats had SIBO 3 months after recovery, and these rats had fewer of the pacemaker cells that drive gut movement¹⁷.
• In the 2015 rat study, antibody levels and loss of vinculin rose with the number of Campylobacter infections and were linked to SIBO¹⁵.

In people, the evidence is indirect. SIBO is more common in IBS with diarrhea¹⁸, the type that most often follows an infection, and anti-CdtB and anti-vinculin antibodies are higher in diarrhea-predominant IBS than in other gut diseases or healthy people¹⁹. Few studies have tested people with confirmed post-infectious IBS for SIBO directly. So an infection that damages gut nerves could leave someone with both post-infectious IBS and SIBO, but SIBO is not shown to be present in most people with post-infectious IBS. If symptoms suggest it, a breath test is the way to check.

Is there a test for post-infectious IBS?

Post-infectious IBS is diagnosed from the history and symptoms, using the criteria above, after ruling out other causes¹. The US IBS guideline suggests a blood test for celiac disease and a stool calprotectin test to rule out inflammatory bowel disease in people with diarrhea symptoms²⁰.

A commercial blood test (IBS-Smart) measures anti-CdtB and anti-vinculin antibodies. In a 2017 study, at least one antibody was positive in 58.1% of people with IBS with diarrhea, 44.0% with mixed IBS, 26.7% with IBS with constipation and 16.3% of healthy people²¹. A positive result makes post-infectious IBS more likely, but a negative one does not rule it out, and an independent 2019 study in Australia could not reproduce its ability to separate IBS from other gut disease²². Our blood tests guide covers the test in detail.

Treatment

The 2019 Rome working team found no treatment proven specifically for post-infectious IBS. It recommends explaining the link between the infection and IBS, reassurance that many people improve, and treating it like IBS of the same type (diarrhea, mixed or constipation)¹.

What the trials show

Treatments from general IBS

• RifaximinRifaximin An antibiotic that is barely absorbed into the bloodstream, so it acts mainly inside the gut. It is a common prescription treatment for SIBO.. In two large 2011 trials in people with IBS without constipation (not selected for a past infection), 2 weeks of rifaximin relieved symptoms in 40.7%, compared with 31.7% on placebo²⁷. The US IBS guideline recommends it for IBS with diarrhea²⁰. In the Campylobacter rat model, rifaximin given at the time of infection reduced later changes in stool¹. See our antibiotics guide.
• Diet. The US IBS guideline recommends a limited trial of the low-FODMAPFODMAPs Fermentable oligo-, di- and monosaccharides and polyols: short-chain carbohydrates that are poorly absorbed and quickly fermented by gut microbes. diet²⁰; see our low-FODMAP guide.
• Gut-directed psychotherapy and medicines for pain or bowel habit are also recommended for IBS in general²⁰.

If SIBO is found

If a breath test shows SIBO, treatment follows SIBO guidance: see our guides to SIBO antibiotics, motility support and relapse prevention. SIBO practitioners often treat post-infectious cases as a motility problem and add a prokineticProkinetic A medication or supplement that stimulates gut movement. Prokinetics are often used after SIBO treatment to support the migrating motor complex and reduce relapse. (a medicine or supplement to stimulate the migrating motor complex) after treatment to lower the chance of relapse. This is practitioner experience rather than trial evidence in post-infectious IBS.

Common questions

Can food poisoning cause IBS?

Yes. About 1 in 10 people develop IBS after infectious gastroenteritis, about four times the usual risk². It is one of the best-established triggers of IBS¹.

Can a stomach flu or virus cause IBS?

Yes, though less often for the long term. After viral gastroenteritis such as norovirus, IBS was common in the first year but much less common later². IBS after COVID-19 has also been reported⁶.

How long does post-infectious IBS last?

It varies. In the Walkerton outbreak, the share with IBS roughly halved between 2 to 3 years and 8 years after the infection⁸. After the Giardia outbreak in Norway, the rate stayed high at 10 years¹⁰. Recovery seems more likely after a virus².

Is post-infectious IBS the same as SIBO?

No. Post-infectious IBS is a symptom-based diagnosis; SIBO is an overgrowth found on a test. The same infection may lead to both by damaging the nerves that control gut movement, as shown in rats¹⁵, but they need to be tested for separately.

Should I take antibiotics for food poisoning to prevent IBS?

No trial shows that. People who took antibiotics during gastroenteritis were more likely to develop IBS, although this may reflect more severe illness². Whether to treat an infection with antibiotics is a decision for your doctor.

How do I know if I have it?

If IBS-type symptoms began right after a gut infection and have lasted for months, talk to your doctor. Our symptom checker can help you prepare, and our diagnosis guide explains which tests to ask about.

Works Cited & Scientific References 27

▼

1. Rome Foundation Working Team Report on post-infection irritable bowel syndrome - Gastroenterology 2019 (PMC)
2. Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: a systematic review and meta-analysis - Gastroenterology 2017 (PMC)
3. Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome - Aliment Pharmacol Ther 2007 (PubMed)
4. Systematic review with meta-analyses: does the pathogen matter in post-infectious irritable bowel syndrome? - Scand J Gastroenterol 2019 (PubMed)
5. Systematic review with meta-analysis: post-infectious irritable bowel syndrome after travellers' diarrhoea - Aliment Pharmacol Ther 2015 (PubMed)
6. Meta-analysis: post-COVID-19 functional dyspepsia and irritable bowel syndrome - Aliment Pharmacol Ther 2023 (PubMed)
7. Impact of Rome IV criteria on the prevalence of post-infection irritable bowel syndrome - Neurogastroenterol Motil 2023 (PubMed)
8. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery - Gut 2010 (PubMed)
9. Irritable bowel syndrome and chronic fatigue 6 years after giardia infection: a controlled prospective cohort study - Clin Infect Dis 2014 (PMC)
10. Prevalence of irritable bowel syndrome and chronic fatigue 10 years after Giardia infection - Clin Gastroenterol Hepatol 2018 (PubMed)
11. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome - Gut 2000 (PMC)
12. Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome - Gut 2014 (PubMed)
13. A new rat model links two contemporary theories in irritable bowel syndrome - Dig Dis Sci 2008 (PubMed)
14. Role of cytolethal distending toxin in altered stool form and bowel phenotypes in a rat model of post-infectious irritable bowel syndrome - J Neurogastroenterol Motil 2012 (PMC)
15. Autoimmunity links vinculin to the pathophysiology of chronic functional bowel changes following Campylobacter jejuni infection in a rat model - Dig Dis Sci 2015 (PubMed)
16. The migrating motor complex: control mechanisms and its role in health and disease - Nat Rev Gastroenterol Hepatol 2012 (PubMed)
17. ICC density predicts bacterial overgrowth in a rat model of post-infectious IBS - World J Gastroenterol 2010 (PMC)
18. Small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis of case-control studies - Am J Gastroenterol 2020 (PubMed)
19. Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects - PLoS One 2015 (PMC)
20. ACG clinical guideline: management of irritable bowel syndrome - Am J Gastroenterol 2021 (PubMed)
21. Assessment of anti-vinculin and anti-cytolethal distending toxin B antibodies in subtypes of irritable bowel syndrome - Dig Dis Sci 2017 (PubMed)
22. Circulating anti-cytolethal distending toxin B and anti-vinculin antibodies as biomarkers in community and healthcare populations with functional dyspepsia and irritable bowel syndrome - Clin Transl Gastroenterol 2019 (PubMed)
23. Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome - Gut 2019 (PMC)
24. Randomized double-blind placebo-controlled study to evaluate the effect of long-acting mesalamine on postinfectious irritable bowel syndrome with diarrhea - Neurogastroenterol Motil 2024 (PubMed)
25. Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome - Aliment Pharmacol Ther 2003 (PubMed)
26. Fecal microbiota transplantation in patients with post-infectious irritable bowel syndrome: a randomized, clinical trial - Front Med 2022 (PMC)
27. Rifaximin therapy for patients with irritable bowel syndrome without constipation - N Engl J Med 2011 (PubMed)